Table 4 Post-workshop attribute reference levels and basis of selection
Cluster | Attribute | Metric | Lower level | Basis | Higher level | Basis |
|---|---|---|---|---|---|---|
Therapeutic Impact | Overall survival | months | 6.2 | BSC | 14.9 | 10% higher than the best performing option |
HRQoL | utility score (EQ-5D) | 0.75 | BSC | 0.9 | 10% higher than the best performing option/ general population | |
Progression free survival | months | 1.9 | BSC | 7.6 | 10% higher than the best performing option | |
Safety Profile | Grade 4 AEs | % of patients | 10 | Median of BSC arm from AMGEN trial and placebo + FOLFIRI arm from VELOUR trial | 0 | Maximum limit of the scale |
Innovation Level | ATC Level 4 | relative market entrance | ≥2nd | Minimum limit of the scale, binary variable | 1st | Maximum limit of the scale, binary variable |
Phase 3 | number of new indications | 0 | Minimum limit of the scale | 21 | 10% higher than the best performing option | |
Marketing authorisation | number of new indications | 0 | Minimum limit of the scale | 3 | 10% higher than the best performing option | |
Posology | duration of administration & frequency of doses | Many hours, every two weeks | Minimum limit of the scale (worst performing option) | Up to an hour, every two weeks | Maximum limit of the scale (best performing option) | |
Socio-economic Impact | Medical costs impact | GBP (£) | 7,086 | 10% higher than the worst performing option | 0 | BSC |